Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802688 | 0.84 | IGF1R (0.63) | IGF1RCCNA2CDK2SRCGSK3B | |
| SCHEMBL801668 | 0.77 | IGF1R (0.53) | IGF1RCCNA2CDK2SRCGSK3B | |
| SCHEMBL13054491 | 0.77 | ULK1 (0.69) | IGF1RCCNA2CDK2SRCGSK3B | |
| SCHEMBL13054888 | 0.77 | IGF1R (0.62) | IGF1R | |
| SCHEMBL13055261 | 0.76 | IGF1R (0.38) | IGF1RCCNA2CDK2SRCGSK3B | |
| SCHEMBL13055236 | 0.76 | ULK1 (0.38) | IGF1RCCNA2CDK2ULK1CCNA1 | |
| SCHEMBL13055229 | 0.75 | IKBKE (0.38) | IGF1RCCNA2CDK2CCNA1NEK1 | |
| SCHEMBL14423530 | 0.75 | AURKA (0.49) | IGF1RSRCGSK3B | |
| SCHEMBL13054450 | 0.75 | ULK1 (0.57) | IGF1RCCNA2CDK2SRCGSK3B | |
| SCHEMBL802295 | 0.74 | IGF1R (0.57) | IGF1RCCNA2CDK2SRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | IGF1R 687/4885CCNA2 333/4885CDK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.